APLI — Appili Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$3.64m
- CA$14.74m
- CA$0.83m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.16 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -7990.21% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.2 | n/a | 1.39 | 0.33 | 0.83 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
Directors
- Ian Mortimer NEC (45)
- Armand Balboni CEO (54)
- Kenneth Howling CFO
- Myriam Triest SDR
- Don Cilla OTH (60)
- Yoav Golan OTH (59)
- Brian Bloom DRC (45)
- Juergen Froehlich IND (65)
- Theresa Matkovits IND (53)
- Rochelle Stenzler IND (67)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 7th, 2015
- Public Since
- June 25th, 2019
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 121,266,120
- Address
- #21-1344 Summer Street, HALIFAX, B3H 0A8
- Web
- https://appilitherapeutics.com/
- Phone
- +1 9024424655
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for APLI
Q1 2026 Appili Therapeutics Inc Earnings Release
Similar to APLI
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
COSCIENS Biopharma
Toronto Stock Exchange
Eupraxia Pharmaceuticals
Toronto Stock Exchange
FAQ
What is the Appili Therapeutics share price?
As of Today at 18:18 UTC, shares in Appili Therapeutics are trading at CA$0.03. This share price information is delayed by 15 minutes.
How has the Appili Therapeutics share price performed this year?
Shares in Appili Therapeutics last closed at CA$0.03 and the price had moved by -14.29% over the past 365 days. In terms of relative price strength the Appili Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -23.73% over the past year.
What are the analyst and broker recommendations for Appili Therapeutics?
The overall consensus recommendation for Appili Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Appili Therapeutics dividend yield?
Appili Therapeutics does not currently pay a dividend.
Does Appili Therapeutics pay a dividend?
Appili Therapeutics does not currently pay a dividend.
When does Appili Therapeutics next pay dividends?
Appili Therapeutics does not currently pay a dividend.
How do I buy Appili Therapeutics shares?
To buy shares in Appili Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Appili Therapeutics?
As of the previous close price of CA$0.03, shares in Appili Therapeutics had a market capitalisation of CA$3.64m.
Where are Appili Therapeutics shares listed?
Here are the trading details for Appili Therapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: APLI
What kind of share is Appili Therapeutics?
Based on an overall assessment of its quality, value and momentum Appili Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Appili Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Appili Therapeutics is CA$0.15. That is 400% above the last closing price of CA$0.03.
Analysts covering Appili Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.04 for the next financial year.
Find out moreWhat is the trend in the Appili Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Appili Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -17.26%.
As of the last closing price of CA$0.03, shares in Appili Therapeutics were trading -16.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Appili Therapeutics PE Ratio?
The Appili Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Appili Therapeutics?
Appili Therapeutics' management team is headed by:
- Ian Mortimer - NEC
- Armand Balboni - CEO
- Kenneth Howling - CFO
- Myriam Triest - SDR
- Don Cilla - OTH
- Yoav Golan - OTH
- Brian Bloom - DRC
- Juergen Froehlich - IND
- Theresa Matkovits - IND
- Rochelle Stenzler - IND